Glendon E. French III Sells 2,326 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 2,326 shares of Pulmonx stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $6.53, for a total value of $15,188.78. Following the completion of the transaction, the director now directly owns 1,069,648 shares of the company’s stock, valued at $6,984,801.44. This represents a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Pulmonx Trading Down 2.1 %

LUNG opened at $6.06 on Thursday. The company has a market cap of $239.30 million, a P/E ratio of -4.12 and a beta of 0.66. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $6.43 and its 200-day moving average is $6.88. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same quarter last year, the business posted ($0.39) earnings per share. Equities research analysts predict that Pulmonx Co. will post -1.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LUNG has been the subject of several recent analyst reports. Wells Fargo & Company cut their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Citigroup reiterated a “neutral” rating and set a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus lowered their price objective on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.75.

Hedge Funds Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of LUNG. 272 Capital LP acquired a new stake in shares of Pulmonx during the third quarter valued at about $25,000. nVerses Capital LLC acquired a new stake in Pulmonx during the 3rd quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Pulmonx during the 2nd quarter worth approximately $37,000. SG Americas Securities LLC bought a new stake in Pulmonx during the 3rd quarter worth approximately $102,000. Finally, Hsbc Holdings PLC acquired a new position in Pulmonx in the 2nd quarter valued at approximately $93,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.